MX2023007918A - Uso de un inhibidor de kras g12c en el tratamiento de canceres. - Google Patents

Uso de un inhibidor de kras g12c en el tratamiento de canceres.

Info

Publication number
MX2023007918A
MX2023007918A MX2023007918A MX2023007918A MX2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A MX 2023007918 A MX2023007918 A MX 2023007918A
Authority
MX
Mexico
Prior art keywords
treatment
inhibitor
cancer
kras
formula
Prior art date
Application number
MX2023007918A
Other languages
English (en)
Spanish (es)
Inventor
Haby Henary
Gataree Ngarmchamnanrith
Agnes L Ang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023007918A publication Critical patent/MX2023007918A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023007918A 2021-01-08 2022-01-07 Uso de un inhibidor de kras g12c en el tratamiento de canceres. MX2023007918A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US202163189625P 2021-05-17 2021-05-17
PCT/US2022/011673 WO2022150628A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Publications (1)

Publication Number Publication Date
MX2023007918A true MX2023007918A (es) 2023-07-13

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007918A MX2023007918A (es) 2021-01-08 2022-01-07 Uso de un inhibidor de kras g12c en el tratamiento de canceres.

Country Status (8)

Country Link
US (1) US20240091230A1 (https=)
EP (2) EP4650006A3 (https=)
JP (1) JP2024502446A (https=)
AU (1) AU2022205969A1 (https=)
CA (1) CA3206523A1 (https=)
MX (1) MX2023007918A (https=)
TW (1) TWI906448B (https=)
WO (1) WO2022150628A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Also Published As

Publication number Publication date
EP4650006A3 (en) 2026-01-14
US20240091230A1 (en) 2024-03-21
AU2022205969A1 (en) 2023-07-06
EP4650006A2 (en) 2025-11-19
TW202241442A (zh) 2022-11-01
WO2022150628A1 (en) 2022-07-14
EP4274579A1 (en) 2023-11-15
TWI906448B (zh) 2025-12-01
CA3206523A1 (en) 2022-07-14
AU2022205969A9 (en) 2024-02-08
JP2024502446A (ja) 2024-01-19

Similar Documents

Publication Publication Date Title
MX2023007918A (es) Uso de un inhibidor de kras g12c en el tratamiento de canceres.
CO2021009879A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CO2021009882A2 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
NZ784224A (en) Parp1 inhibitors
AR123996A2 (es) Compuestos tricíclicos novedosos como agentes antineoplásicos
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
JOP20190254A1 (ar) مركبات مضادة للأورام
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
CL2025003576A1 (es) Composición farmacéutica que comprende un compuesto de quinazolina.
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
MX385562B (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d] [1,3] -oxazin-2-ona como mutantes idh1 e inhibidores de idh2.
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CR20130247A (es) Compuestos tricíclicos de la pi3k y métodos de uso
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
EA201490472A1 (ru) Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
DOP2011000129A (es) 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CO2022000481A2 (es) Inhibidores de enzimas
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
MX2022006500A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.